Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Single-blind, Randomized, Placebo-controlled, Sequential Design Phase 1 Study With the Inclusion of Two Double-blind Nested Crossover Parts to Investigate the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

Next Previous
Trial Profile

A Single-center, Single-blind, Randomized, Placebo-controlled, Sequential Design Phase 1 Study With the Inclusion of Two Double-blind Nested Crossover Parts to Investigate the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary) ; Citalopram
  • Indications Insomnia; Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 13 Nov 2023 According to Sosei Heptares, New Drug Application submitted to the Japanese Pharmaceuticals and Medical Devices Agency for the approval of daridorexant (ACT541468), a novel dual orexin receptor antagonist, for the treatment of adult patients with insomnia
  • 04 Jun 2021 Results published in the European Neuropsychopharmacology
  • 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top